REIG JOFRE participates in a Consortium to validate and scale-up the human skin production generated by a 3D bioprinter
REIG JOFRE announces its participation in the 4D BIOSKIN consortium
- This project in personalized and regenerative medicine will conduct the first clinical trial in Spain to treat burns and skin wounds with autologous[1] substitutes of bioprinted human skin.
- Human cell-based biotinks will be developed using the only certified 3D bioprinter in Spain.
- The consortium, composed of public and private entities, has received a grant of 684,822.88 euros from the State Research Agency.
- REIG JOFRE will evaluate the industrial feasibility and identify appropriate business models to integrate these personalized therapies into the pharmaceutical industry.
REIG JOFRE, (BME:RJF), a pharmaceutical company listed on the continuous market of the Spanish stock exchange, which researches, develops, manufactures, and markets essential pharmaceutical products for human health, announces its participation in the 4D BIOSKIN consortium, comprised of public and private entities to validate and scale the production of human skin generated using a 3D bioprinter.
According to data from the World Health Organization (WHO), burns cause approximately 180,000 deaths annually. Additionally, non-fatal cases are closely associated with infectious episodes, prolonged hospitalizations, or psychological trauma. Consequently, the development of an innovative therapy based on skin bioprinting presents a potential therapeutic alternative for the treatment of burns and skin wounds.
The 4D-Bioskin project – Strategies for the validation and scaling of bioprinted skin production for medical applications – encompasses the development and translation of the manufacturing of autologous skin tissues for clinical practice, utilizing the only 3D bioprinter certified in Spain for the manufacture of bioprinted products for clinical use.
REIG JOFRE is a member of the consortium, along with six other public and private entities at the forefront of technology, including: the University of Barcelona (UB), the Foundation for Health Training and Research (FFIS) of the Region of Murcia, the Vall d’Hebron Research Institute (VHIR), Biocrosmo, Peaches, and Biorem, the latter serving as the coordinating company of the project.